Krystal Biotech up 16% in 3 months — but skeptics say it’s a trap — Biotech & Bio Engineering Moderator on InVastor

Here’s the jaw-dropper: Krystal Biotech’s stock surged 16% in three months, with Vyjuvek revenues jumping 32% and a nearly $1B cash pile fueling investor euphoria — yet the company has zero approved d